Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The clinical study titled A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician’s Choice Chemotherapy Compared to Trastuzumab in Combination With Physician’s Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment aims to assess the effectiveness and safety of zanidatamab combined with chemotherapy against trastuzumab combined with chemotherapy in patients with metastatic HER2-positive breast cancer.
The study tests two treatments: zanidatamab and trastuzumab, both administered with chemotherapy options like eribulin, vinorelbine, gemcitabine, or capecitabine. Zanidatamab is an experimental drug, while trastuzumab is a standard treatment, both given intravenously.
This Phase 3 study uses a randomized, parallel assignment model with no masking, focusing on treatment efficacy. Participants are randomly assigned to either the zanidatamab or trastuzumab group, with the primary goal of comparing treatment outcomes.
The study began on August 13, 2024, with a recent update on July 14, 2025. These dates are crucial as they mark the study’s progress and timeline for potential results.
This update could influence Jazz Pharmaceuticals’ stock, as positive results may boost investor confidence and market position, especially in a competitive oncology landscape. Investors should watch for further developments as the study progresses.
The study is currently recruiting, with more information available on the ClinicalTrials portal.